KRAS IN-44 (Compound S2C2M2) is a PDE6D degrader. It inhibits PDE6D-dependent KRAS transport and downstream signaling pathways. Additionally, KRAS IN-44 downregulates EGF-induced phosphorylation of PI3K, AKT, and mTOR. It promotes apoptosis and exhibits antitumor activity against hepatoblastoma.
Target-Kategorie:
PDE|||Ras|||PI3K|||Apoptosis|||Akt|||mTOR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
